Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9-Aminocamptothecin in Advanced Ovarian Cancer
NCT00001427Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 1995
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 9-aminocamptothecin in ovarian cancer, sponsored by National Cancer Institute. Primary endpoint: Response Rate. Started Jan 1995; status: completed.
02
Drugs
9-aminocamptothecin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00001427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001427.